ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BL-ARC002

Its studies are led by Sichuan Biokin Pharmaceutical.

Furthest: phase 1, since May 9, 20262 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical22 open or runningphase 1since May 9, 2026May 9, 2026Dec 2027phase 1 · NCT07591155

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 9, 2026First study: phase 1 study in Lung NeoplasmsFirst studyNCT07591155 · 22 planned · China
  2. Aug 10, 2026Phase 1 study in Digestive System NeoplasmsNCT07763652 · 22 planned · China

Ahead

  1. Dec 2027Primary completion: phase 1 study in Lung NeoplasmsNCT07591155
  2. Dec 2028Primary completion: phase 1 study in Digestive System NeoplasmsNCT07763652

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07763652Digestive System Neoplasms · China1RecruitingDec 202822
NCT07591155Lung Neoplasms · China1RecruitingDec 202722

How it is read

Names in the registry

  • “BL-ARC002”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.